跳至主要内容
临床试验/NCT02754193
NCT02754193已完成不适用

Effects of Induced Moderate HYPOthermia on Mortality in Cardiogenic Shock Patients Rescued by Veno-arterial ExtraCorporeal Membrane Oxygenation (ECMO)

Central Hospital, Nancy, France20 个研究点 分布在 1 个国家目标入组 334 人开始时间: 2016年10月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
334
试验地点
20
主要终点
All-cause Mortality

研究概览

简要总结

A multicenter, prospective, controlled, randomized (moderate hypothermia 33°C≤ T°C ≤34°C) during 24 hours ± 1h versus normothermia (36°C≤ T°C ≤37°C), comparative open trial will be conducted on two parallel groups of patients with cardiogenic shock treated with VA-ECMO.

The HYPO-ECMO trial will test the hypothesis that moderate hypothermia (temperature between 33°C≤ T°C ≤34°C) associated with VA-ECMO support results in a reduction in 30-day mortality in comparison with the normothermia group (36°C≤ T°C ≤37°C).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Intubated patients with cardiogenic shock treated with VA-ECMO
  • Patient affiliated to social security plan

排除标准

  • VA-ECMO after cardiac surgery for heart transplantation or lung transplantation or left or biventricular assist device implantation
  • VA-ECMO for acute poisoning with cardio-toxic drugs
  • Pregnancy
  • Uncontrolled bleeding (bleeding despite medical intervention (surgery or drugs))
  • Implantation of VA ECMO under cardiac massage with a duration of cardiac massage >45minutes
  • Out of hospital refractory cardiac arrest
  • Cerebral deficit with fixed dilated pupils
  • Participation in another interventional research involving therapeutic modifications
  • Patient moribund on the day of randomization
  • Irreversible neurological pathology
  • Minor patients
  • Patients under tutelage

结局指标

主要结局

All-cause Mortality

时间窗: Day 30

The study objective is to determine whether early moderate hypothermia (33°C≤ T°C ≤34°C) is superior to normothermia (37°C ± 0.3°C) in patients with cardiogenic shock treated with VA-ECMO with respect to 30-day mortality

次要结局

  • Death(day 30, Day 60, Day 180)
  • Lactate(up to 180 days (from date of randomization until ECMO weaning))
  • Mechanical ventilation(baseline, day 30, day 60 and day 180)
  • Renal replacement therapy(from baseline until day 30, day 60, day 180)
  • packed red blood cells transfused(Hour 48, Day 7)
  • All-cause mortality(Hour 48, Day 7, Day 60, day 180)
  • Stroke(Day 30, Day 60, Day 180)
  • Venous Arterial ECMO duration(up to 180 days (from date of randomization until ECMO weaning))
  • cardiac transplant(day 30, Day 60, Day 180)
  • SOFA score(from baseline until Day 30)
  • Intensive care unit stay(Day 30; Day 60; Day 180)
  • escalation to Left Ventricular Assist Device(day 30, Day 60, Day180)
  • Cumulated amount of administered fluids(up to 180 days (from date of randomization until ECMO weaning))
  • Cumulated amount of vasopressors use(up to 180 days (from date of randomization until ECMO weaning))
  • Infection(Hour 48, Day 7, Day 30, Day 60, day 180)
  • hospitalization stay(Day 30; Day 60; Day 180)
  • bleeding complications(Hour 48, Day 7)

研究者

发起方
Central Hospital, Nancy, France
申办方类型
Other
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验